Document is current
Any future updates will be listed below
-
Authors
Tirado, Carlos F.
Washburn, Stephanie N.
Covalin, Alejandro
Hedenberg, Caroline
Vanderpool, Heather
Benner, Caroline
Powell, Daniel P.
McWade, Melanie A.
Khodaparast, Navid https://orcid.org/0000-0003-4621-1295
- License Information
-
More Information
Article History
Received: 17 June 2022
Accepted: 29 July 2022
First Online: 18 August 2022
Declarations
:
: This trial was conducted in accordance with ICH Good Clinical Practices Guidelines, FDA regulations, and followed the Consolidated Standards of Reporting Trials reporting guidelines. Institutional Review Board approval from Western Copernicus Group (20191239; Puyallup, WA) was obtained prior to study conduct. Written informed consent was obtained from all participants prior to any study-related procedures.
: Not applicable.
: NK, SW, DP, CB, HV, MM and AC are employees and have private equity (stock options or other ownership interest) in Spark Biomedical. CT has private equity in and is a paid consultant of Spark Biomedical.
